Paper Details

  1. Home
  2. Paper Details

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Author: BebinE Martina, BelousovaElena D, BerkowitzNoah, BisslerJohn J, BrechenmacherThomas, FlaminiJ Robert, FranzDavid N, FrostMichael D, JozwiakSergiusz, KingswoodJ Chris, KohrmanMichael H, KorfBruce R, KupermanRachel A, SparaganaSteven P, SteinKaren, WuJoyce Y

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the use of everolimus, a medication that blocks a specific cellular pathway (mTOR inhibitor), in treating a type of tumor (angiomyolipoma) in patients with tuberous sclerosis complex (TSC). The study specifically focuses on patients with TSC who also have a type of brain tumor (subependymal giant cell astrocytoma, SEGA).
Paper Details　
Original Abstract of the Article :
Tuberous sclerosis complex (TSC) is characterized by benign tumours in multiple organs, including the brain, kidneys, skin, lungs and heart. Our objective was to evaluate everolimus, an mTOR inhibitor, in the treatment of angiomyolipoma in patients with subependymal giant cell astrocytoma (SEGA) ass...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852219/

データ提供：米国国立医学図書館（NLM）

Everolimus for Renal Angiomyolipoma in Tuberous Sclerosis Complex

This research focuses on the potential therapeutic benefits of everolimus, an mTOR inhibitor, in patients with tuberous sclerosis complex (TSC), a rare genetic disorder characterized by benign tumors in various organs. This study specifically examined the effectiveness of everolimus in treating renal angiomyolipoma (a type of kidney tumor) in patients with TSC who were also being treated for subependymal giant cell astrocytoma (SEGA), a brain tumor associated with TSC. The results of the study offer promising evidence for the use of everolimus in managing these challenging conditions.

Everolimus: A Potential Therapeutic Option for TSC-Related Tumors

This study sheds light on the therapeutic potential of everolimus, an mTOR inhibitor, in patients with TSC. The findings suggest that everolimus may effectively manage renal angiomyolipoma, a type of kidney tumor, in patients with TSC who are also being treated for SEGA, a brain tumor associated with TSC. This is an encouraging discovery for patients with TSC, offering a potential treatment for two debilitating conditions with a single medication.

Living with Tuberous Sclerosis Complex: Hope on the Horizon

Living with TSC can be challenging, as the disorder can affect multiple organs and systems. This research offers a glimmer of hope for individuals with TSC, suggesting that everolimus may effectively manage both renal angiomyolipoma and SEGA. This could potentially improve the quality of life for patients with TSC, allowing them to live healthier and more fulfilling lives. It's like a desert oasis, providing relief and nourishment for individuals who have been traversing a challenging landscape.

Dr. Camel's Conclusion

Navigating the complexities of TSC can feel like traversing a vast and unforgiving desert. This research offers a potential oasis, suggesting that everolimus may provide relief for patients with TSC-related tumors. It's a promising discovery, offering hope for individuals with this challenging condition.

Date :
  1. Date Completed 2014-11-07
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24729041

DOI: Digital Object Identifier

PMC4852219

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.